Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mattersburg

55 clinical trials in Mattersburg, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mattersburg at a glance
55
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

55 trials in Mattersburg

Open in trial search

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:Astrazeneca AB

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Cardiac failure

Recruiting

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:PF-07328948
  • Sponsor:Pfizer Inc.

Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Medical University Of Graz

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen - Cilag International

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Insel Gruppe AG

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mattersburg

What the registry says about research in the country

01 Cardiovascular Diseases

In Mattersburg, clinical trial activity in cardiovascular diseases is focused on reducing the risk of serious heart complications and improving long-term outcomes for people with atherosclerotic cardiovascular disease.

  • Studies in atherosclerotic cardiovascular disease and broader cardiovascular disease
  • Research on preventing major heart events and related complications
  • Work aimed at improving treatment effectiveness for high-risk patients

These trials are helping assess whether new therapies can better protect patients from heart attacks, cardiovascular death, and other major events.

02 Nutritional and Metabolic Diseases

Clinical research in nutritional and metabolic diseases in this Austrian city is closely linked to obesity, overweight, and related metabolic risk factors that can affect heart and kidney health.

  • Trials involving obesity and overweight
  • Studies connecting weight-related conditions with cardiovascular disease
  • Research evaluating new approaches to improve metabolic health

The main goal is to understand whether emerging treatments can lower long-term disease burden and support better prevention.

03 Cardiovascular Risk Reduction

Several trials are examining whether investigational therapies can reduce the chance of first or repeat major cardiovascular events in participants with elevated risk factors.

  • Atherosclerotic Cardiovascular Disease and event prevention
  • Elevated Lp(a) as a key risk factor under study
  • Testing new options to reduce heart-related morbidity and mortality

This research focuses on whether better risk control can help prevent heart attacks, urgent procedures, and other serious outcomes.

04 Kidney and Cardiometabolic Health

Some studies also look beyond the heart, examining whether treatments can help preserve kidney function in people with overlapping cardiometabolic conditions.

  • Chronic Kidney Disease in combination with heart risk
  • People living with obesity and related complications
  • Trials exploring whether therapy can support both heart and kidney outcomes

These projects aim to find approaches that address multiple health concerns at once, which is especially important for patients with complex chronic disease.

05 Lipoprotein(a) Research

A notable area of investigation is Lipoprotein(a), or Lp(a), where researchers are testing whether lowering this inherited risk marker can reduce cardiovascular events.

  • Elevated Lp(a) and first major cardiovascular events
  • Studies focused on preventing coronary heart disease and myocardial infarction
  • Evaluating new strategies for people at heightened genetic risk

This work could improve prevention for patients whose heart risk remains high despite standard care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.